Principal Financial Group Inc. trimmed its position in shares of Denali Therapeutics Inc (NASDAQ:DNLI) by 28.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 128,900 shares of the company’s stock after selling 51,869 shares during the period. Principal Financial Group Inc. owned approximately 0.14% of Denali Therapeutics worth $2,538,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Denali Therapeutics during the 1st quarter worth approximately $142,000. New York State Common Retirement Fund purchased a new stake in shares of Denali Therapeutics during the 1st quarter worth approximately $173,000. D.A. Davidson & CO. purchased a new stake in shares of Denali Therapeutics during the 1st quarter worth approximately $197,000. American International Group Inc. purchased a new stake in shares of Denali Therapeutics during the 1st quarter worth approximately $203,000. Finally, UBS Group AG raised its holdings in shares of Denali Therapeutics by 5,364.5% during the 1st quarter. UBS Group AG now owns 10,929 shares of the company’s stock worth $215,000 after acquiring an additional 10,729 shares in the last quarter. 63.04% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have recently issued reports on the company. Zacks Investment Research cut Denali Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 14th. ValuEngine raised Denali Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $23.25.

Shares of DNLI opened at $16.43 on Friday. Denali Therapeutics Inc has a 1 year low of $12.32 and a 1 year high of $25.79.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.39). The firm had revenue of $1.65 million during the quarter, compared to analyst estimates of $3.00 million. research analysts anticipate that Denali Therapeutics Inc will post -1.2 earnings per share for the current year.

About Denali Therapeutics

Denali Therapeutics, Inc engages in the development of portfolio of therapeutic candidates for neurodegenerative diseases. Its programs comprises of lysosomal function pathway, glial biology pathway, and cellular homeostasis. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth in 2013 and is headquartered in San Francisco, CA.

Recommended Story: Stock Symbols Definition, Examples, Lookup

Institutional Ownership by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.